Miguel is a lawyer and a patent attorney with over 20 years of international experience in different areas of IP law, including litigation, opinion drafting, patent prosecution, and licensing.

Miguel holds degrees in Chemistry and Economics, a Master’s degree in Molecular Biotechnology, and a Juris Doctor in Law. He is a United States patent attorney and a partially qualified European patent attorney. Previously,

Miguel was Senior Director of Intellectual Property at Sanifit Therapeutics, where he assisted in the sale of the company to the Vifor Pharma Group in 2022 in the largest transaction recorded to-date in the life sciences sector in Spain. He has worked before in Norbrook Laboratories, Laboratorios Esteve, BioSidus, and Del Monte.

Miguel’s practice has concentrated on the IP, regulatory, and business aspects of biotechnological and pharmaceutical inventions, including biosimilar products (e.g., EPO, GCSF, GH, monoclonal antibodies), small molecules, vaccines (e.g., Coronavirus, HIV, HP, cancer), diagnostic tests, orphan drugs, and gene therapy.

He has drafted and prosecuted U.S., EP, and foreign patent applications, rendered non-infringement, validity, patentability, and inventorship opinions, and drafted and interpreted indemnification, employment, and non-compete agreements related to IP. In addition, he has prepared and prosecuted trademark and copyright registrations and counseled clients on a range of intellectual property issues including portfolio management, patent strategy, and design-around efforts.

Miguel has also participated in negotiations with international entities such as Institut Pasteur, Institut Curie, INSERM, Aventis Pasteur, Ospedale San Raffaele, Istituto Dermopatico dell’Immacolata, UCB-Schwarz Pharma, Merck Serono, TEVA, the University of Wisconsin, the University of Massachusetts, the University of Maryland, the Institute of Human Virology, the Warren Institute, Unigene, Pestka Laboratories, and Genzyme, among others.